9 Dec 12 Dr. Julie Brahmer on the PD-1 Targeted Immunotherapy BMS-93655 Clinical Trial

9 Dec 12 Dr. Julie Brahmer on the PD-1 Targeted Immunotherapy BMS-93655 Clinical Trial
Julie R. Brahmer, MD, associate professor of oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, discusses a phase I clinical trial that investigated the experimental agent BMS-93655, a targeted immunotherapy agent that blocks the programmed death-1 (PD-1) receptor that is expressed by activated T cells, in multiple tumor types. Find out more, at www.onclive.com
Video Rating: 0 / 5